- Home
- NXTC vs EQ Comparison
NXTC vs EQ Comparison
Compare NXTC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- EQ
- Stock Information
- Founded
- NXTC 2015
- EQ 2017
- Country
- NXTC United States
- EQ United States
- Employees
- NXTC N/A
- EQ 35
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- EQ Health Care
- Exchange
- NXTC Nasdaq
- EQ Nasdaq
- Market Cap
- NXTC 13.9M
- EQ 13.1M
- IPO Year
- NXTC 2019
- EQ 2018
- Fundamental
- Price
- NXTC $6.17
- EQ $0.40
- Analyst Decision
- NXTC Strong Buy
- EQ Buy
- Analyst Count
- NXTC 3
- EQ 3
- Target Price
- NXTC $33.00
- EQ $3.00
- AVG Volume (30 Days)
- NXTC 299.6K
- EQ 553.1K
- Earning Date
- NXTC 08-04-2025
- EQ 08-07-2025
- Dividend Yield
- NXTC N/A
- EQ N/A
- EPS Growth
- NXTC N/A
- EQ N/A
- EPS
- NXTC N/A
- EQ N/A
- Revenue
- NXTC N/A
- EQ $30,406,000.00
- Revenue This Year
- NXTC N/A
- EQ N/A
- Revenue Next Year
- NXTC N/A
- EQ N/A
- P/E Ratio
- NXTC N/A
- EQ N/A
- Revenue Growth
- NXTC N/A
- EQ N/A
- 52 Week Low
- NXTC $2.69
- EQ $0.27
- 52 Week High
- NXTC $20.76
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- EQ 56.38
- Support Level
- NXTC $4.75
- EQ $0.36
- Resistance Level
- NXTC $5.23
- EQ $0.45
- Average True Range (ATR)
- NXTC 0.56
- EQ 0.06
- MACD
- NXTC 0.10
- EQ 0.00
- Stochastic Oscillator
- NXTC 86.74
- EQ 59.32
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.